Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Pfizer develops new series of PDE5 inhibitors for once-daily dosing

Sep. 12, 2008

QuatRx initiates second phase III study of Ophena in postmenopausal vaginal syndrome

Sep. 10, 2008

CV Therapeutics initiates phase I CVT-3619 trial for cardiometabolic diseases

Sep. 10, 2008

BioSante clinical results for Pill-Plus triple hormone therapy

Sep. 9, 2008

Histalean begins phase II female obesity study

Sep. 9, 2008

Mutual submits NDA to FDA for antihyperlipidemic drug MPC-028

Sep. 9, 2008

Lilly to fund rodent studies of Corcept's selective GRII receptor antagonist CORT-108297

Sep. 9, 2008

Yaz, a new low-dose oral contraceptive, launched in Europe by Bayer Schering Pharma

Sep. 8, 2008

Novel therapeutic agents for obesity reported in recent Taisho patent

Sep. 5, 2008

Recent patents describe new antidiabetic agents

Sep. 5, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model
BioWorld Science
Camp4 Therapeutics Corp. has highlighted new preclinical data for CMP-002, the company’s lead investigational antisense oligonucleotide (ASO) therapeutic...